Hims & Hers and Novo Nordisk Settle GLP-1 Litigation, Pivot to Collaboration

The sudden pivot from a high-stakes legal battle to a commercial partnership between Hims & Hers Health and Novo Nordisk marks a watershed moment for the telehealth and pharmaceutical industries. For several years, the legal landscape for GLP-1 medications—specifically semaglutide, marketed as Ozempic and Wegovy—was defined by Novo Nordisk’s aggressive pursuit of companies offering compounded versions of the drug. This settlement suggests a strategic realization that a collaborative distribution model may be more profitable and less legally volatile than protracted litigation over patent infringement and FDA compounding exemptions.

Novo Nordisk has filed dozens of lawsuits against medical spas and compounding pharmacies, but Hims & Hers was a particularly high-profile target due to its scale and public market presence. The core of the dispute rested on Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding pharmacies to produce versions of patented drugs when they are on the FDA’s official shortage list. As supply chains for Wegovy and Ozempic stabilized throughout 2025 and early 2026, the legal window for compounded versions began to close, putting Hims & Hers in a precarious regulatory position. By settling now, Hims & Hers avoids the risk of a court ruling that could have shuttered a significant portion of its weight-loss revenue stream.

“

The sudden pivot from a high-stakes legal battle to a commercial partnership between Hims & Hers Health and Novo Nordisk marks a watershed moment for the telehealth and pharmaceutical industries.

By settling and entering into a collaboration, Novo Nordisk gains access to a massive, digitally native distribution channel that has already mastered the patient acquisition and telehealth consultation process. Hims & Hers, meanwhile, secures its long-term viability by moving away from the legally gray area of compounding and toward an authorized, brand-name partnership. This move likely signals to other telehealth providers that the era of the 'compounded GLP-1 gold rush' is coming to an end. The path forward for the industry now appears to involve legitimate licensing and distribution agreements with Big Pharma, rather than relying on the temporary protections of the FDA shortage list.